A strategy for the clinical remission of acute lymphoblastic leukemia elicited by treatment of β‑thalassemia major: A case report
- Miguel A. Palomo‑Colli
- Marta Zapata‑Tarres
- Osvaldo D. Castelán‑Martínez
- Luis E. Juárez‑Villegas
- Lourdes P. Córdova‑Hurtado
Published online on: December 8, 2017
Acute lymphoblastic leukemia (ALL) has been suggested as a long‑term complication in patients with β‑thalassemia major (β‑TM). A 12‑months‑old male patient was diagnosed with β‑TM. The patient required a blood transfusion weekly for 2 years. At the age of 4 years, a splenectomy was performed due to massive splenomegaly and frequent transfusion requirements. The histopathological analysis of the spleen revealed extensive hemosiderosis. ALL‑L1 with the T immunophenotype and without central nervous system (CNS) involvement was diagnosed when the patient was 5 years old, and treated with anti‑leukemic combination chemotherapy and CNS radiotherapy. The patient completed 24 months of treatment and has been in complete remission for 7 years, without long‑term adverse events.